JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 23.39 Billion KRW | 6.04% |
| 2022 | 22.06 Billion KRW | 4.69% |
| 2021 | 21.07 Billion KRW | 25.56% |
| 2020 | 16.78 Billion KRW | 6.4% |
| 2019 | 15.77 Billion KRW | 7.54% |
| 2018 | 14.67 Billion KRW | 20.74% |
| 2017 | 12.15 Billion KRW | -12.11% |
| 2016 | 13.82 Billion KRW | -6.46% |
| 2015 | 14.78 Billion KRW | 20.15% |
| 2014 | 12.3 Billion KRW | 13.86% |
| 2013 | 10.8 Billion KRW | 14.85% |
| 2012 | 9.4 Billion KRW | 10.75% |
| 2011 | 8.49 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 25.47 Billion KRW | 2.63% |
| 2024 Q1 | 24.82 Billion KRW | 6.1% |
| 2023 Q4 | 23.39 Billion KRW | 5.36% |
| 2023 Q3 | 22.2 Billion KRW | -5.28% |
| 2023 Q1 | 24.32 Billion KRW | 10.23% |
| 2023 FY | 23.39 Billion KRW | 6.04% |
| 2023 Q2 | 23.44 Billion KRW | -3.61% |
| 2022 Q1 | 23.25 Billion KRW | 10.35% |
| 2022 FY | 22.06 Billion KRW | 4.69% |
| 2022 Q2 | 21.68 Billion KRW | -6.77% |
| 2022 Q3 | 20.42 Billion KRW | -5.82% |
| 2022 Q4 | 22.06 Billion KRW | 8.05% |
| 2021 FY | 21.07 Billion KRW | 25.56% |
| 2021 Q1 | 16.51 Billion KRW | -1.63% |
| 2021 Q2 | 17.69 Billion KRW | 7.19% |
| 2021 Q3 | 18.94 Billion KRW | 7.03% |
| 2021 Q4 | 21.07 Billion KRW | 11.26% |
| 2020 FY | 16.78 Billion KRW | 6.4% |
| 2020 Q1 | 17.7 Billion KRW | 12.21% |
| 2020 Q2 | 20.02 Billion KRW | 13.13% |
| 2020 Q3 | 17.32 Billion KRW | -13.48% |
| 2020 Q4 | 16.78 Billion KRW | -3.13% |
| 2019 Q3 | 17.74 Billion KRW | -3.75% |
| 2019 Q1 | 16.52 Billion KRW | 12.66% |
| 2019 FY | 15.77 Billion KRW | 7.54% |
| 2019 Q4 | 15.77 Billion KRW | -11.1% |
| 2019 Q2 | 18.43 Billion KRW | 11.56% |
| 2018 Q3 | 13.48 Billion KRW | -4.26% |
| 2018 FY | 14.67 Billion KRW | 20.74% |
| 2018 Q4 | 14.67 Billion KRW | 8.8% |
| 2018 Q2 | 14.08 Billion KRW | 14.1% |
| 2018 Q1 | 12.34 Billion KRW | 1.58% |
| 2017 Q1 | 12.6 Billion KRW | -8.86% |
| 2017 Q2 | 13.76 Billion KRW | 9.28% |
| 2017 Q3 | 13.04 Billion KRW | -5.26% |
| 2017 Q4 | 12.15 Billion KRW | -6.86% |
| 2017 FY | 12.15 Billion KRW | -12.11% |
| 2016 FY | 13.82 Billion KRW | -6.46% |
| 2016 Q4 | 13.82 Billion KRW | -8.93% |
| 2016 Q3 | 15.18 Billion KRW | 17.12% |
| 2016 Q2 | 12.96 Billion KRW | 0.0% |
| 2015 Q4 | 14.78 Billion KRW | 0.0% |
| 2015 FY | 14.78 Billion KRW | 20.15% |
| 2014 FY | 12.3 Billion KRW | 13.86% |
| 2013 FY | 10.8 Billion KRW | 14.85% |
| 2012 FY | 9.4 Billion KRW | 10.75% |
| 2011 FY | 8.49 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 47.005% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 80.146% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 74.334% |
| HANDOK Inc. | 94.46 Billion KRW | 75.23% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -10.147% |
| Yuhan Corporation | 284.75 Billion KRW | 91.783% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 79.883% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -43.915% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 91.898% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | 27.747% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 62.092% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -20.134% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | 22.727% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 51.603% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 47.005% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | 25.102% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 33.482% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 51.383% |
| JW Holdings Corporation | 147.58 Billion KRW | 84.146% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 72.35% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 91.05% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 77.945% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 56.608% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | 13.332% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 28.03% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 78.684% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 47.005% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 87.596% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 90.313% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 77.945% |
| Yuhan Corporation | 284.75 Billion KRW | 91.783% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 81.323% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 62.252% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 90.995% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 77.945% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 70.606% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 52.386% |
| CKD Bio Corp. | 69.08 Billion KRW | 66.129% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 77.732% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 66.903% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 56.716% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 56.608% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 87.986% |
| Boryung Corporation | 189.8 Billion KRW | 87.672% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 58.828% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 62.092% |